GSK plc (LON:GSK) Given Average Recommendation of “Hold” by Analysts

GSK plc (LON:GSK) has earned an average recommendation of “Hold” from the seven analysts that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is GBX 2,034.29.

A number of equities analysts recently issued reports on the company. Shore Capital Group restated a “buy” rating on shares of GSK in a research note on Wednesday, March 25th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a GBX 1,900 target price on shares of GSK in a research note on Monday, June 8th. Citigroup reduced their target price on GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Jefferies Financial Group restated a “buy” rating and issued a GBX 2,500 target price on shares of GSK in a research note on Thursday, May 28th. Finally, Berenberg Bank restated a “hold” rating and issued a GBX 2,000 target price on shares of GSK in a research note on Thursday, March 26th.

GSK Stock Performance

Shares of GSK stock opened at GBX 1,918 on Monday. The firm has a market capitalization of £76.92 billion, a price-to-earnings ratio of 13.50, a price-to-earnings-growth ratio of 1.24 and a beta of 0.29. The company has a debt-to-equity ratio of 106.74, a current ratio of 0.79 and a quick ratio of 0.73. The business has a fifty day moving average of GBX 1,960.15 and a 200 day moving average of GBX 1,965.61. GSK has a 1 year low of GBX 1,288.61 and a 1 year high of GBX 2,282.

GSK (LON:GSK) last issued its earnings results on Wednesday, April 29th. The company reported GBX 46.50 earnings per share (EPS) for the quarter. The company had revenue of GBX 762.90 billion during the quarter. GSK had a return on equity of 35.78% and a net margin of 17.78%. As a group, research analysts expect that GSK will post 175.980975 earnings per share for the current year.

Insider Transactions at GSK

In other news, insider Wendy Becker bought 4,000 shares of GSK stock in a transaction that occurred on Wednesday, April 29th. The stock was bought at an average price of GBX 1,963 per share, for a total transaction of £78,520. In the last ninety days, insiders acquired 4,012 shares of company stock valued at $7,875,917. Company insiders own 0.31% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.